Orchestra BioMed Holdings, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OBIO research report →
Companyorchestrabiomed.com
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.
- CEO
- David Hochman
- IPO
- 2020
- Employees
- 70
- HQ
- New Hope, PA, US
Price Chart
Valuation
- Market Cap
- $237.13M
- P/E
- -4.55
- P/S
- 7.25
- P/B
- 4.87
- EV/EBITDA
- -3.87
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 99.27%
- Op Margin
- -167.96%
- Net Margin
- -166.96%
- ROE
- -137.99%
- ROIC
- -62.63%
Growth & Income
- Revenue
- $33.48M · 1169.22%
- Net Income
- $-52,701,000 · 13.64%
- EPS
- $-1.38 · 16.87%
- Op Income
- $-51,807,000
- FCF YoY
- 2.74%
Performance & Tape
- 52W High
- $5.42
- 52W Low
- $2.20
- 50D MA
- $4.26
- 200D MA
- $3.83
- Beta
- 0.52
- Avg Volume
- 215.96K
Get TickerSpark's AI analysis on OBIO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 18, 26 | Aryeh Jason | buy | 665 |
| May 15, 26 | Aryeh Jason | buy | 8,971 |
| May 15, 26 | Hochman David P | buy | 5,000 |
| May 14, 26 | Fain Eric S | buy | 20,000 |
| Apr 27, 26 | RTW INVESTMENTS, LP | other | 1,250,032 |
| Apr 27, 26 | RTW INVESTMENTS, LP | sell | 32 |
| Apr 27, 26 | RTW INVESTMENTS, LP | other | 1,250,032 |
| Mar 25, 26 | Sherman Darren | other | 33,317 |
| Mar 25, 26 | Aiello Joshua | other | 241 |
| Mar 25, 26 | Hochman David P | other | 32,438 |
Our OBIO Coverage
We haven't published any research on OBIO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate OBIO Report →